JGP Global Gestao de Recursos Ltda. Has $301,000 Stock Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

JGP Global Gestao de Recursos Ltda. reduced its stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 90.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,378 shares of the company's stock after selling 51,000 shares during the period. JGP Global Gestao de Recursos Ltda.'s holdings in Rhythm Pharmaceuticals were worth $301,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the stock. Raleigh Capital Management Inc. bought a new stake in shares of Rhythm Pharmaceuticals during the 4th quarter worth approximately $28,000. R Squared Ltd bought a new stake in Rhythm Pharmaceuticals during the fourth quarter worth $44,000. ORG Wealth Partners LLC acquired a new stake in shares of Rhythm Pharmaceuticals in the 3rd quarter valued at $63,000. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Rhythm Pharmaceuticals by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,211 shares of the company's stock valued at $114,000 after purchasing an additional 391 shares during the last quarter. Finally, KBC Group NV raised its holdings in shares of Rhythm Pharmaceuticals by 78.2% during the 4th quarter. KBC Group NV now owns 2,251 shares of the company's stock worth $126,000 after buying an additional 988 shares in the last quarter.

Rhythm Pharmaceuticals Stock Performance

Shares of NASDAQ RYTM traded down $1.01 during midday trading on Thursday, reaching $60.01. The stock had a trading volume of 361,332 shares, compared to its average volume of 514,180. The company's 50 day moving average price is $57.37 and its 200 day moving average price is $53.19. Rhythm Pharmaceuticals, Inc. has a twelve month low of $35.17 and a twelve month high of $68.58. The firm has a market cap of $3.69 billion, a price-to-earnings ratio of -13.86 and a beta of 2.14.

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last released its earnings results on Tuesday, November 5th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.80) by $0.07. Rhythm Pharmaceuticals had a negative net margin of 230.07% and a negative return on equity of 367.36%. The business had revenue of $33.20 million for the quarter, compared to analyst estimates of $32.52 million. During the same quarter in the previous year, the business earned ($0.76) earnings per share. Rhythm Pharmaceuticals's revenue for the quarter was up 47.6% on a year-over-year basis. Equities analysts forecast that Rhythm Pharmaceuticals, Inc. will post -4.33 earnings per share for the current fiscal year.

Analysts Set New Price Targets

RYTM has been the topic of a number of recent analyst reports. TD Cowen lifted their target price on Rhythm Pharmaceuticals from $55.00 to $65.00 and gave the company a "buy" rating in a research report on Wednesday, November 6th. Jefferies Financial Group assumed coverage on shares of Rhythm Pharmaceuticals in a research report on Thursday, January 2nd. They set a "buy" rating and a $80.00 price objective for the company. Bank of America raised their target price on shares of Rhythm Pharmaceuticals from $48.00 to $52.00 and gave the company a "neutral" rating in a research report on Monday, October 14th. The Goldman Sachs Group upped their price target on shares of Rhythm Pharmaceuticals from $59.00 to $66.00 and gave the stock a "buy" rating in a report on Thursday, December 5th. Finally, Guggenheim started coverage on Rhythm Pharmaceuticals in a report on Monday, October 21st. They set a "buy" rating and a $70.00 price objective on the stock. One analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $68.09.

Insider Transactions at Rhythm Pharmaceuticals

In other Rhythm Pharmaceuticals news, EVP Jennifer Kayden Lee sold 1,447 shares of the firm's stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $59.43, for a total value of $85,995.21. Following the completion of the sale, the executive vice president now directly owns 4,038 shares in the company, valued at approximately $239,978.34. This trade represents a 26.38 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Joseph Shulman sold 13,281 shares of Rhythm Pharmaceuticals stock in a transaction on Monday, November 11th. The shares were sold at an average price of $66.44, for a total transaction of $882,389.64. The disclosure for this sale can be found here. In the last ninety days, insiders sold 88,826 shares of company stock valued at $5,833,370. Corporate insiders own 5.60% of the company's stock.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.